Questions discussed in this category
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
Do you generally recommend anti-diarrheals, dietary modifications, or consider this an unacceptable side effect and move to other therapies?
At what doses do you start? and how do you titrate therapy?
If a patient has received a kidney transplant for SLE-LN and is stable and doing well. Managed by their transplant team and on chronic immunosuppressi...
Are there specific guidelines for managing this patient population?
Nussbaum et al., PMID 38195100
21963210411952321528214742148721213213092063820635204051978519403180991706917054164471564514834
Papers discussed in this category
Am J Transplant, 2021 Feb 23
Transplantation, 2009 Aug 15
J Rheumatol, 2017 May 15
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023 Feb 13
Therapeutic drug monitoring, 2022 Jun 01
Transplant international : official journal of the European Society for Organ Transplantation, 2019 Oct 07
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024 Jul 19
European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2021 Dec 06
Kidney international, 2018-07
BMC nephrology, 2019-02-14
Clinical transplantation, 2020 Nov 22
Arthritis care & research, 2023 Nov 28
Kidney360, 2022 Aug 25
Circulation, 2019-06-18